Histiocytosis, Langerhans-Cell
A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder.
Subtype terms (1)
More specific conditions that are subtypes of Histiocytosis, Langerhans-Cell in the MeSH hierarchy.
- Eosinophilic Granuloma
11 drugs (9 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (2)
Phase 3 trials (13)
Phase 2 trials (38)
- thalidomide
- methylprednisolone
- tioguanine
- denosumab
- ly-3023414
- afuresertib
- olaparib
- bvd-523
- lenalidomide
- clofarabine
- dabrafenib
- selinexor
- etanercept
- erdafitinib
- tacrolimus
- trametinib
- larotrectinib
- leucovorin
- palbociclib
- mirdametinib
- zarnestra
- vemurafenib
- cyclosporine
- cyclophosphamide
- tazemetostat
- Anti-thymocyte Globulin (Rabbit)
- Selpercatinib
- mesna
- rituximab
- ivosidenib
- +8 more
Phase 1 trials (3)
Other trials (4)
Organizations
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (19)
- Celgene
- Genentech
- Sanofi
- Accenture
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- National Cancer Institute (NCI)
- Hellenic Army
- Cornell University
- Harvard University
- Hellenic Society for the Study of Bone Metabolism
- Tsinghua University
- Mesoblast, Inc.
- University of Texas at Houston
- Pennsylvania State University
- Methodist Cancer Center, Houston, Texas
- University of Paris
- Cookies for Kids' Cancer
- St. Baldrick's Foundation
- Chinese Academy of Medical Sciences
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (2)